Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab

• Published in: Pediatric nephrology (Berlin, West) Vol. 32; no. 1; pp. 181 - 184
• Main Authors: Vivarelli, Marina, Colucci, Manuela, Bonanni, Alice, Verzani, Martina, Serafinelli, Jessica, Emma, Francesco, Ghiggeri, Gianmarco
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2017; Springer; Springer Nature B.V
• Subjects: Adolescent; Analgesics; Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal - therapeutic use; B-Lymphocytes; Brief Report; Child, Preschool; Complications and side effects; Cyclosporine - therapeutic use; Dosage and administration; Drug Hypersensitivity; Drug Resistance; Drug therapy; Dyspnea; Humans; Immunosuppressive Agents - therapeutic use; Kidney diseases; Lymphocytes; Male; Medicine; Medicine & Public Health; Methylprednisolone - therapeutic use; Monoclonal antibodies; Mycophenolic Acid - therapeutic use; Nephrology; Nephrotic syndrome; Nephrotic Syndrome - drug therapy; Ofatumumab; Patients; Pediatrics; Prednisone - therapeutic use; Remission (Medicine); Rituximab; Rituximab - adverse effects; Steroids; Treatment Outcome; Urology; Italy; Rituximab; Steroid-dependent nephrotic syndrome; Adverse reaction; Steroid-resistant nephrotic syndrome; Ofatumumab; Children
• ISSN: 0931-041X; 1432-198X; 1432-198X
• DOI: 10.1007/s00467-016-3498-y

Background Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions. Case-Diagnosis/Treatment Patient 1, a 14-year-old boy with SDNS since the age of 2, was treated with oral prednisone, cyclosporine A (CsA) and mycophenolate mofetil. A first infusion of rituximab at age 12 years was well tolerated, but this was followed by a prolonged relapse unresponsive to oral prednisone, mycophenolate mofetil and CsA. A second rituximab infusion was attempted, but treatment was interrupted due to severe dyspnea. Treatment with a humanized anti-CD20 monoclonal antibody, ofatumumab, was then attempted. The patient experienced a mild allergic reaction and maintained remission despite interruption of all treatment at >12 months of follow-up. Patient 2, a 3-year-old boy who presented at 18 months with nephrotic syndrome initially resistant to treatment with oral prednisone, was given with three intravenous boluses of methylprednisolone followed by CsA and achieved remission. Upon steroid discontinuation, the NS relapsed. Prednisone was restarted and treatment with a single dose of rituximab was never completed due to a severe allergic reaction. Ofatumumab infusion was uneventful, and he maintained remission during the follow-up period (>12 months) despite interruption of prednisone therapy. B cells reappeared at 7 months in both patients. Conclusions Ofatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab.